Atossa Genetics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings results on Friday. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12), FiscalAI reports.

Atossa Genetics Trading Down 1.2%

Shares of ATOS traded down $0.07 during midday trading on Friday, reaching $5.60. The stock had a trading volume of 31,395 shares, compared to its average volume of 61,457. The company’s 50-day moving average is $5.18 and its 200 day moving average is $8.28. The company has a market capitalization of $48.22 million, a price-to-earnings ratio of -1.56 and a beta of 1.25. Atossa Genetics has a 12-month low of $3.76 and a 12-month high of $19.35.

Analyst Ratings Changes

Several research firms recently weighed in on ATOS. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a report on Monday, April 20th. Ascendiant Capital Markets dropped their price target on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Finally, HC Wainwright upped their price objective on Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $36.33.

Institutional Investors Weigh In On Atossa Genetics

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Atossa Genetics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after purchasing an additional 9,627 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in Atossa Genetics in the second quarter worth $26,000. JPMorgan Chase & Co. lifted its stake in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the last quarter. Bank of America Corp DE boosted its position in Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares during the period. Finally, &PARTNERS bought a new position in shares of Atossa Genetics during the fourth quarter valued at about $25,000. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.